Home The Word Brain My Amedeo FAQ Privacy About


Hanzi Hunter

Learning 500 Chinese characters in 30 days is possible.

Abstract • About

  Leukemia

  Free Subscription


Articles published in Exp Hematol

Retrieve available abstracts of 48 articles:
HTML format



Single Articles


    March 2026
  1. UEDA K, Sato Y, Minakawa K, Miura S, et al
    Loss of Ezh2 precipitates lethal disease progression in a mouse model of Calr-mutated myeloproliferative neoplasms.
    Exp Hematol. 2026;155:105350.
    PubMed     Abstract available


  2. NISHIKII H, Kikuchi R, Kimura T, Saito M, et al
    Tumor necrosis factor from leukemic environment stimulates hematopoietic stem/progenitor cells toward megakaryocyte/myeloid lineage bias.
    Exp Hematol. 2026;155:105332.
    PubMed     Abstract available


    February 2026
  3. YAN Y, Kato H, Sano S, Furukawa E, et al
    Heme Synthesis Inhibition Induces the Intrinsic Apoptosis Pathway in Leukemia with OSGIN1 Upregulation.
    Exp Hematol. 2026 Feb 13:105401. doi: 10.1016/j.exphem.2026.105401.
    PubMed     Abstract available


  4. KHAN AB, Huntly BJP
    Taking the direct route: menin inhibitors go straight to the frontline in KMT2A-rearranged acute leukemia.
    Exp Hematol. 2026 Feb 4:105386. doi: 10.1016/j.exphem.2026.105386.
    PubMed     Abstract available


  5. DUGUID A, Malouf C, Nitsche L, Halsey C, et al
    Mixed-lineage leukemia cells undergo unique adaptations in the CNS niche.
    Exp Hematol. 2026;154:105347.
    PubMed     Abstract available


  6. IAQUINTA G, Lagana A, Tamburini A, Tatarelli C, et al
    Germline heterozygous SH2B3 p.Glu78Lys variant: a three-patient case series with myeloproliferative neoplasms.
    Exp Hematol. 2026;154:105333.
    PubMed     Abstract available


    January 2026
  7. MAHDAVI L, Alikarami F, Goodrow H, Lenard A, et al
    Upfront menin-inhibitor resistance in multiply pretreated leukemias.
    Exp Hematol. 2026;153:105268.
    PubMed     Abstract available


    December 2025
  8. GORSCH E, Rudat S, Arnone M, Keppeler H, et al
    Laminin Receptor Characterization in Acute Myeloid Leukemia: Integrin alpha7beta1 Defines leukemic cells with Migratory Potential.
    Exp Hematol. 2025 Dec 25:105363. doi: 10.1016/j.exphem.2025.105363.
    PubMed     Abstract available


  9. WANG J, Xu J
    Splenic Erythroblasts Fuels Leukemia Progression Through Metabolic Crosstalk.
    Exp Hematol. 2025 Dec 15:105351. doi: 10.1016/j.exphem.2025.105351.
    PubMed     Abstract available


    November 2025
  10. ROY R, Paul T, Das PK, Sinha S, et al
    ERK-mTOR crosstalk suppresses Autophagy and upregulates proteasomal degradation pathway to confer Chronic Myeloid Leukemia cells resistant to Imatinib.
    Exp Hematol. 2025 Nov 28:105330. doi: 10.1016/j.exphem.2025.105330.
    PubMed     Abstract available


  11. VARGHESE P, Garcia-Cuellar MP, Slany RK
    The myeloid transcription factor Elf1 regulates genes with function in innate immunity.
    Exp Hematol. 2025;151:104864.
    PubMed     Abstract available


    October 2025
  12. CONNEELY SE, Quezada A, Kurtz KJ, Zhang N, et al
    Cohesin haploinsufficiency is tolerated in Cbfb::MYH11-driven murine acute myeloid leukemia.
    Exp Hematol. 2025 Oct 29:105287. doi: 10.1016/j.exphem.2025.105287.
    PubMed     Abstract available


    September 2025
  13. ERNST P, Kyei P, Yokoyama A
    KMT2A-rearranged leukemia: from mechanism to drug development.
    Exp Hematol. 2025 Sep 6:105247. doi: 10.1016/j.exphem.2025.105247.
    PubMed     Abstract available


  14. SANGHA G, Huntly BJP
    Gene regulatory complexes: their role and regulation across normal and malignant hematopoiesis.
    Exp Hematol. 2025;149:104821.
    PubMed     Abstract available


  15. YOSHIDA S, Onozawa M, Yokoyama S, Matsukawa T, et al
    Peposertib suppresses generation of FLT3-internal tandem duplication formed by contralateral double nicks.
    Exp Hematol. 2025;149:104819.
    PubMed     Abstract available


    August 2025
  16. WANG J, Xu L, Wang G, Wu W, et al
    ZC3H13 facilitates the progression of acute myeloid leukemia through m6A-FOXP1-mediated metabolic reprogramming.
    Exp Hematol. 2025 Aug 6:104862. doi: 10.1016/j.exphem.2025.104862.
    PubMed     Abstract available


  17. SAMAREH B, Klimenkova O, Aghaallaei N, Cheng L, et al
    NAMPT-mediated deacetylation of HCLS1 protein promotes clonogenic growth of pediatric CML cells.
    Exp Hematol. 2025;148:104801.
    PubMed     Abstract available


    July 2025
  18. FOSSELTEDER J, Brauchart T, Schlacher A, Sconocchia T, et al
    Engineered cytokine-expressing MSCs support ex vivo culture of human HSPCs and AML cells.
    Exp Hematol. 2025;147:104790.
    PubMed     Abstract available


    June 2025
  19. ZHANG A, Qiu S
    Advances of RARalpha fusion genes in acute promyelocytic leukemia.
    Exp Hematol. 2025 Jun 7:104822. doi: 10.1016/j.exphem.2025.104822.
    PubMed     Abstract available


    May 2025
  20. LU J, Xue X, Wang H, Hao Y, et al
    Notch1 activation and inhibition in T cell acute lymphoblastic leukemia subtypes.
    Exp Hematol. 2025 May 8:104771. doi: 10.1016/j.exphem.2025.104771.
    PubMed     Abstract available


  21. CISA-WIECZOREK S, Hernandez-Alvarez MI, Parreno M, Munoz JP, et al
    D816V KIT mutation induces mitochondrial morphologic and functional changes through BNIP3 downregulation in human myeloid cell lines ROSA and TF-1.
    Exp Hematol. 2025;145:104748.
    PubMed     Abstract available


    April 2025
  22. FOURNIER M, Dubuissez M, Neault M, Delisle JS, et al
    Unbiased analysis of NUP98-KDM5A-induced murine leukemia reveals phenotypic heterogeneity recapitulating human disease subtypes.
    Exp Hematol. 2025 Apr 19:104791. doi: 10.1016/j.exphem.2025.104791.
    PubMed     Abstract available


    March 2025
  23. GUL AZ, Selek S, Bekiroglu S, Demirel M, et al
    Serum NMR metabolomics in distinct subtypes of hematologic malignancies.
    Exp Hematol. 2025;143:104710.
    PubMed     Abstract available


  24. SARCHI M, Doulatov S
    Understanding Human Oncogene Function and Cooperativity in Myeloid Malignancy Using iPSCs.
    Exp Hematol. 2025;143:104697.
    PubMed     Abstract available


  25. GUIRGUIS AA
    RNA methylation: where to from here for hematologic malignancies?
    Exp Hematol. 2025;143:104694.
    PubMed     Abstract available


    February 2025
  26. TACHIBANA T, Izumi A, Arai S, Takeda T, et al
    Preconditioning intervention before allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.
    Exp Hematol. 2025 Feb 12:104746. doi: 10.1016/j.exphem.2025.104746.
    PubMed     Abstract available


  27. DE GROOT AP, Nguyen H, Pouw JS, Weersing E, et al
    CBX7 inhibitors affect H3K9 methyltransferase-regulated gene repression in leukemic cells.
    Exp Hematol. 2025;142:104691.
    PubMed     Abstract available


    January 2025
  28. AMOR AR, Enlund S, Sinha I, Jiang Q, et al
    A Distinct Alternative mRNA Splicing Profile Identifies the Oncogenic CD44 Transcript Variant 3 in KMT2A-Rearranged Pediatric T-cell Acute Lymphoblastic Leukemia Cells.
    Exp Hematol. 2025 Jan 8:104712. doi: 10.1016/j.exphem.2025.104712.
    PubMed     Abstract available


    November 2024
  29. QU Y, Shourabizadeh H, Subramanian A, Aleman DM, et al
    DIFFERENTIAL IMPACT OF CD34+ CELL DOSE FOR DIFFERENT AGE GROUPS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE LEUKEMIA: A MACHINE LEARNING-BASED DISCOVERY.
    Exp Hematol. 2024 Nov 22:104684. doi: 10.1016/j.exphem.2024.104684.
    PubMed     Abstract available


    October 2024
  30. KOHNKE T, Feng Y, Majeti R
    A New Era of Functional Experimentation in Human Hematopoiesis and Leukemia Research.
    Exp Hematol. 2024 Oct 1:104652. doi: 10.1016/j.exphem.2024.104652.
    PubMed     Abstract available


    September 2024
  31. KHAMARI R, Degand C, Fovez Q, Trinh A, et al
    Key role of glutamine metabolism in persistence of leukemic cells upon exposition to FLT3 tyrosine kinase inhibitors.
    Exp Hematol. 2024;137:104253.
    PubMed     Abstract available


    August 2024
  32. CAMIOLO G, Mullen CG, Ottersbach K
    Mechanistic insights into the developmental origin of pediatric hematologic disorders.
    Exp Hematol. 2024;136:104583.
    PubMed     Abstract available


    June 2024
  33. ONG KOK, Mok MMH, Niibori-Nambu A, Du L, et al
    Activation of NOTCH signaling impedes cell proliferation and survival in acute megakaryoblastic leukemia.
    Exp Hematol. 2024 Jun 12:104255. doi: 10.1016/j.exphem.2024.104255.
    PubMed     Abstract available


  34. STRAUBE J, Janardhanan Y, Haldar R, Bywater MJ, et al
    Immune control in acute myeloid leukemia.
    Exp Hematol. 2024 Jun 12:104256. doi: 10.1016/j.exphem.2024.104256.
    PubMed     Abstract available


  35. ROGERS JH, Rosen A, Reyes JM, Ketkar S, et al
    Dose-dependent effects of Dnmt3a in an inducible murine model of Kras(G12D)-driven leukemia.
    Exp Hematol. 2024 Jun 2:104248. doi: 10.1016/j.exphem.2024.104248.
    PubMed     Abstract available


  36. XU JJ, Viny AD
    Chromatin organization in myelodysplastic syndrome.
    Exp Hematol. 2024;134:104216.
    PubMed     Abstract available


    May 2024
  37. ZHOU Q, Li Z, Xi Y
    EV-mediated intercellular communication in acute myeloid leukemia: Transport of genetic materials in the bone marrow microenvironment.
    Exp Hematol. 2024;133:104175.
    PubMed     Abstract available


    March 2024
  38. PANTING RG, Kotecha RS, Cheung LC
    The critical role of the bone marrow stromal microenvironment for development of drug screening platforms in leukemia.
    Exp Hematol. 2024 Mar 27:104212. doi: 10.1016/j.exphem.2024.104212.
    PubMed     Abstract available


  39. GOSWAMI M, Bose PD
    Gut Microbial Dysbiosis in the Pathogenesis of Leukemia: An Immune-based Perspective.
    Exp Hematol. 2024 Mar 23:104211. doi: 10.1016/j.exphem.2024.104211.
    PubMed     Abstract available


  40. LIU Q, Zhai Y, Hui Y, Chen J, et al
    Identification of Red blood cell distribution width as a prognostic factor in acute myeloid leukemia.
    Exp Hematol. 2024 Mar 18:104206. doi: 10.1016/j.exphem.2024.104206.
    PubMed     Abstract available


    February 2024
  41. TANAKA T, Kudo K, Kanezaki R, Yuzawa K, et al
    Anti-leukemic effect of azacitidine, a DNA methyltransferase inhibitor, on cell lines of myeloid leukemia associated with Down syndrome.
    Exp Hematol. 2024 Feb 9:104179. doi: 10.1016/j.exphem.2024.104179.
    PubMed     Abstract available


  42. RANDALL J, Evans K, Watts B, Kosasih HJ, et al
    IN VIVO ACTIVITY OF THE SECOND-GENERATION PROTEASOME INHIBITOR IXAZOMIB AGAINST PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA XENOGRAFTS.
    Exp Hematol. 2024 Feb 4:104176. doi: 10.1016/j.exphem.2024.104176.
    PubMed     Abstract available


  43. MERZ AMA, Platzbecker U
    Beyond the horizon: emerging therapeutic approaches in myelodysplastic neoplasms.
    Exp Hematol. 2024;130:104130.
    PubMed     Abstract available


    December 2023
  44. ALQAZZAZ MA, Luciani GM, Vu V, Machado RM, et al
    Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations.
    Exp Hematol. 2023 Dec 8:S0301-472X(23)01773-3. doi: 10.1016/j.exphem.2023.
    PubMed     Abstract available


  45. BUROCZIOVA M, Grusanovic S, Vanickova K, Kosanovic S, et al
    Chronic inflammation promotes cancer progression as a second hit.
    Exp Hematol. 2023;128:30-37.
    PubMed     Abstract available


    October 2023
  46. XIE Y, Tan L, Wu K, Li D, et al
    MiR-455-3p mediates PPARalpha through UBN2 to promote apoptosis and autophagy in acute myeloid leukemia cells.
    Exp Hematol. 2023 Oct 5:S0301-472X(23)01734-4. doi: 10.1016/j.exphem.2023.
    PubMed     Abstract available


    September 2023
  47. GUARNERA L, Santinelli E, Galossi E, Cristiano A, et al
    Microenvironment in Acute Myeloid Leukemia: focus on senescence mechanisms, therapeutic interactions and future directions.
    Exp Hematol. 2023 Sep 21:S0301-472X(23)01705.
    PubMed     Abstract available


  48. HAN L, Wu J, Lyu X, Yu J, et al
    Genetic Mutation Signature for Relapse Prediction in Normal Karyotype Acute Myeloid Leukemia.
    Exp Hematol. 2023 Sep 20:S0301-472X(23)01706.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum